U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07134088) titled 'A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia' on Aug. 14.
Brief Summary: The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.
Study Start Date: Nov. 21, 2025
Study Type: INTERVENTIONAL
Condition:
Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
Intervention:
DRUG: Blinatumomab
Blinatumomab will be administered as a SC injection for up to 5 cycles (each cycle will be 35 days).
Recruitment Status: NOT_YET_...